Hepatitis B virus (HBV) is a compact, DNA-based virus that infects liver cells and can persist for decades, causing chronic liver disease, cirrhosis, and liver cancer. An estimated 350 million people worldwide carry chronic HBV infection, with prevalence varying dramatically by region.1PubMed Central. Epidemiology and Prevention of Hepatitis B Virus Infection Despite effective vaccines and antiviral drugs, the virus remains difficult to eliminate from the body once it establishes itself, largely because of a resilient form of its DNA that hides inside the nucleus of infected cells.
How the Virus Is Built
HBV is small by viral standards. The complete infectious particle, called a Dane particle, measures roughly 44 nanometers across. It has two shells: an outer envelope made of surface antigen proteins (HBsAg) embedded in a lipid layer, and an inner core built from core antigen protein arranged in a geometric, icosahedral shape. Inside the core sits the viral genome, a circular piece of partially double-stranded DNA.2PubMed Central. Hepatitis B small surface antigen particles are octahedral
One quirk of HBV biology is that the virus massively overproduces its surface proteins during chronic infection. These excess proteins self-assemble into small, roughly 22-nanometer spheres and tubular filaments that far outnumber the actual infectious particles in a patient’s blood.2PubMed Central. Hepatitis B small surface antigen particles are octahedral These decoy particles contain no DNA and cannot cause infection on their own, but they can absorb antibodies, effectively distracting the immune system. The surface antigen in the blood is also the basis of the most common screening test for hepatitis B.
Getting Inside Liver Cells
HBV has a strong preference for human liver cells, and the reason comes down to a single receptor on the surface of those cells: a bile-salt transporter called NTCP. Under normal circumstances, NTCP moves bile acids from the blood into liver cells, a routine housekeeping function. HBV hijacks this transporter by latching onto it with a region of its large surface protein called the preS1 domain, which triggers the cell to swallow the virus along with the receptor.3PubMed Central. Tyrosine 146 of the Human Na(+)/Taurocholate Cotransporting Polypeptide (NTCP) Is Essential for Its Hepatitis B Virus (HBV) Receptor Function and HBV Entry into Hepatocytes Blocking this interaction prevents infection entirely. Experiments using a synthetic peptide derived from the virus’s own attachment region showed that knocking down NTCP in laboratory liver cells stopped both HBV and hepatitis D virus from getting in.4PubMed. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes
The dependence on NTCP also explains why HBV infects so few species. The receptor differs enough between humans, mice, and other animals that the virus cannot efficiently bind to most non-human versions. This has historically made studying HBV in animal models challenging.
The cccDNA Problem
Once inside a liver cell, HBV’s partially double-stranded DNA travels to the nucleus, where host enzymes repair it into a fully closed, circular molecule called cccDNA. This cccDNA wraps around histone proteins and takes on a chromosome-like structure, sometimes described as a “beads-on-a-string” arrangement under electron microscopy.5Cancer Biology & Medicine. Research progress in hepatitis B virus covalently closed circular DNA From this stable platform, the virus produces all of its RNA transcripts, including the pregenomic RNA that serves as the template for making new viral DNA through reverse transcription.6PubMed. Hepatitis B virus biology and life cycle
This molecular template is the central reason HBV is so hard to cure. The cccDNA sits in the nucleus as a minichromosome, and current antiviral drugs do not destroy it. They suppress the virus’s ability to copy new DNA, but the template persists, ready to resume viral production if treatment is stopped.7PubMed Central. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential The viral protein HBx plays a key role in maintaining cccDNA activity and keeping viral replication going, which makes it a target of interest for researchers hoping to silence the minichromosome.5Cancer Biology & Medicine. Research progress in hepatitis B virus covalently closed circular DNA
How HBV Spreads
The dominant route of transmission depends heavily on where in the world you look. In high-prevalence regions, particularly parts of East Asia and sub-Saharan Africa where more than 8% of the population carries chronic infection, the main route is mother-to-child transmission during or shortly after birth. In low-prevalence areas like the United States and northern Europe, where chronic infection rates fall below about 0.5%, sexual contact and intravenous drug use account for most new cases among adults.1PubMed Central. Epidemiology and Prevention of Hepatitis B Virus Infection Between these extremes sit intermediate-prevalence regions where a mix of early-childhood horizontal transmission through household contact and adult-acquired infection both contribute.8PubMed. Global epidemiology of hepatitis B virus
HBV is far more infectious than HIV. A needlestick exposure to HBV-positive blood carries a much higher risk of infection than a comparable exposure to HIV-positive blood, which is why healthcare settings have long prioritized hepatitis B vaccination for staff. The virus can also survive outside the body on surfaces for days, making it transmissible through shared razors, toothbrushes, or unsterilized medical equipment.
Why Age at Infection Changes Everything
Few viruses demonstrate the importance of timing as starkly as HBV. When an infant contracts the virus around birth, the chance of developing chronic infection runs between 70% and 90%. For children under five, the risk drops to roughly 20% to 50%. Older children and adults face only about a 5% to 10% chance of becoming chronic carriers.9PubMed. Epidemiology of hepatitis B The paradox is that acute infection tends to be milder in young children (often showing no symptoms at all), while adults more often experience obvious illness with jaundice and fatigue. Yet the quiet infections in babies are the dangerous ones, because the immature immune system tolerates the virus rather than clearing it, setting up lifelong carriage that raises the risk of cirrhosis and liver cancer decades later.10PubMed. Hepatitis B virus: the importance of age at infection
This age-dependent pattern is the fundamental reason universal infant vaccination has had such an outsized impact in high-prevalence countries. Preventing perinatal and early-childhood infection eliminates the cohort most likely to become chronic carriers.
How the Virus Damages the Liver
HBV itself is not directly toxic to liver cells in most situations. The damage comes largely from the immune response. In chronic infection, the immune system mounts a persistent but ultimately ineffective attack on infected liver cells, producing ongoing inflammation, cell death, and scar tissue.11PubMed Central. Potential mechanisms of hepatitis B virus induced liver injury Over time, this cycle of inflammation and healing leads to fibrosis, and eventually cirrhosis, in which normal liver architecture is replaced by scar tissue that blocks blood flow and impairs organ function.
Chronic infection also reshapes the immune landscape in ways that favor the virus. Regulatory immune cells expand, exhaustion markers appear on T cells, and inflammatory signaling goes haywire, all of which weaken the antiviral response while sustaining tissue damage.12PubMed Central. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression This dual failure, inability to clear the virus combined with ongoing immune-mediated injury, is what makes chronic hepatitis B a progressive disease.
The Path to Liver Cancer
HBV is one of the most well-established causes of liver cancer (hepatocellular carcinoma, or HCC). The virus promotes cancer through several overlapping mechanisms. It integrates fragments of its DNA into the host cell genome, which can disrupt genes that control cell growth or activate cancer-promoting genes.13PubMed Central. Hepatitis B virus integration and hepatocarcinogenesis The viral HBx protein interferes with signaling pathways tied to cell division and programmed cell death, tipping the balance toward uncontrolled growth.14PubMed. Hepatitis B virus-induced hepatocellular carcinoma Advanced sequencing has identified recurrent spots in the human genome where HBV DNA tends to insert itself, suggesting the integration is not random but preferentially hits vulnerable cancer-related genes.
Importantly, HBV-related liver cancer can occur even in patients without cirrhosis, distinguishing it from hepatitis C-related cancer, which almost always arises on a background of advanced scarring. This means that HBV carriers need ongoing cancer surveillance regardless of their fibrosis stage.
Reading the Blood Tests
Diagnosing and monitoring hepatitis B relies on a panel of blood markers, each telling a different part of the story. The surface antigen (HBsAg) is the hallmark of active infection: if it is present, the person is infected. Antibodies to the surface antigen (anti-HBs) indicate immunity, either from vaccination or from past cleared infection. The e antigen (HBeAg) generally signals high viral replication and high infectivity, while its corresponding antibody (anti-HBe) often signals a transition to lower replication.
Clinicians increasingly use quantitative HBsAg levels to track the phase of chronic infection. Levels tend to be highest early in the immune-tolerant phase (when the virus replicates freely with little liver damage) and decline as the immune system begins to exert control. Quantitative HBsAg has shown high accuracy for distinguishing the immune-tolerant phase from the immune-clearance phase, when the body is actively fighting the virus and liver inflammation is present.15PubMed. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection Higher baseline HBsAg levels in patients who are otherwise in a low-replication phase can also flag those at risk of viral reactivation.16Journal of Hepatology. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective
Vaccination and Long-Lasting Immune Memory
The hepatitis B vaccine is one of the most successful viral vaccines ever developed. It uses recombinant HBsAg to train the immune system without any risk of infection. The standard three-dose series produces protective antibody levels in the vast majority of recipients.
A common worry is that protection fades as antibody levels drop over the years. Research has put that concern largely to rest. A study following Thai infants born to highly infectious mothers (both HBsAg- and HBeAg-positive) found that immune memory persisted for at least 20 years after vaccination. Even when circulating antibodies had fallen below detection thresholds, a booster dose triggered a rapid, robust response, confirming that the immune system “remembered” the virus.17PubMed Central. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers Separate work confirmed that even people who had lost detectable antibodies after vaccination still carried memory T and B cells capable of mounting a protective response if exposed to the virus.18PubMed. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination The strength of that memory tracks with the initial vaccine response, which is why using highly immunogenic vaccine formulations matters.19PubMed. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory
Antiviral Treatment With Nucleos(t)ide Analogues
For people living with chronic hepatitis B who need treatment, the backbone of therapy is a class of oral drugs called nucleos(t)ide analogues. These drugs are converted into active forms inside cells and then compete with the virus’s own building blocks during DNA synthesis, blocking the viral polymerase from copying new DNA.20Current Opinion in Virology. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance The two first-line options are entecavir and tenofovir, both of which suppress viral replication powerfully with a very high barrier to drug resistance.21PLOS ONE. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis
These drugs are taken as a single daily pill, are well tolerated, and can maintain viral suppression indefinitely. The catch is that they suppress the virus without eliminating it. Because the cccDNA template in the nucleus remains intact, stopping the drug risks a viral rebound. Most patients who start treatment face indefinite therapy, which raises practical concerns about cost, adherence, and long-term side effects, particularly bone and kidney effects associated with certain tenofovir formulations.22Journal of Antimicrobial Chemotherapy. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B
Pegylated Interferon and the Idea of Functional Cure
The other established treatment approach uses pegylated interferon-alpha, an injectable immune-boosting drug given for a defined course, usually 48 weeks. Unlike nucleos(t)ide analogues, which directly block the virus, interferon works by ramping up the immune system’s attack. It does not suit every patient and comes with significant side effects including fatigue, mood changes, and blood count drops, but it offers something the oral drugs rarely achieve: a chance at “functional cure,” defined as sustained loss of HBsAg after treatment ends.
Pegylated interferon has shown particular promise when added for patients who have already achieved partial viral suppression on oral antivirals. It can improve liver scarring in patients with compensated cirrhosis and has been associated with lower rates of liver cancer after curative cancer treatment.23PubMed Central. Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection Among patients who achieve HBsAg loss and develop anti-HBs antibodies (seroconversion) by the end of interferon therapy, the durability of functional cure is substantially better than in those who lose HBsAg without seroconversion. One study found that HBsAg returned in only about 10% of patients who seroconverted, compared with over 37% of those who did not, within a roughly two-year follow-up period.24PubMed Central. The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment
Drug Resistance and Immune Escape Mutations
HBV mutates as it replicates, and some of those mutations can cause trouble. Drug resistance mutations alter the viral polymerase so that antiviral drugs no longer fit properly. With older drugs like lamivudine, resistance was a major problem: mutations at key positions emerged frequently during treatment. The newer first-line agents, entecavir and tenofovir, have much higher barriers to resistance, but pre-existing resistance mutations have been detected even in patients who have never been treated.25PubMed. Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B
A separate category of concern is immune escape mutations, changes in the surface antigen that let the virus dodge vaccine-induced or natural antibodies. These mutations cluster in a region of HBsAg called the major hydrophilic region. One study found immune escape mutations in over 40% of the chronic hepatitis B patients examined, with drug resistance mutations present in about 38% of the same cohort.26PubMed Central. Immune Escape and Drug Resistance Mutations in Patients with Hepatitis B Virus Infection: Clinical and Epidemiological Implications The practical worry is that escape mutants could, in theory, infect vaccinated individuals or evade diagnostic tests that rely on detecting the standard form of HBsAg. So far, these scenarios remain uncommon, but they underscore the importance of surveillance.
The Search for New Drugs
Because current therapies suppress the virus without curing it, a large research effort is aimed at achieving functional cure for more patients. The pipeline includes several distinct strategies: drugs that block the virus from entering cells via NTCP, molecules that interfere with the assembly of new viral capsids, RNA-interference agents (siRNAs and antisense oligonucleotides) that silence viral gene expression, and compounds designed to degrade or silence cccDNA itself.27PubMed Central. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents Immune-based approaches are also in development, including toll-like receptor agonists that stimulate the innate immune system, checkpoint inhibitors borrowed from cancer immunotherapy, and therapeutic vaccines designed to retrain exhausted HBV-specific immune cells.
Many of these candidates are already in mid- to late-stage clinical trials, and the current expectation is that functional cure will eventually require combinations attacking the virus at multiple points simultaneously, much as combination therapy transformed HIV treatment.28PubMed. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Hepatitis D and Why It Depends on Hepatitis B
Hepatitis D virus (HDV) is a peculiar pathogen: it cannot replicate or spread on its own. HDV carries a tiny RNA genome but has no genes for making its own outer coat. Instead, it borrows the surface proteins of HBV, wrapping itself in HBsAg before budding out of infected cells. This makes HBV infection an absolute prerequisite for HDV infection.29Journal of Clinical and Translational Hepatology. Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte
The clinical significance is that HDV coinfection makes everything worse. When someone acquires both viruses at the same time, the acute illness tends to be more severe. When HDV arrives as a superinfection in someone already carrying chronic HBV, up to 80% of cases become chronic, and the combined infection accelerates progression toward fibrosis and decompensated cirrhosis.29Journal of Clinical and Translational Hepatology. Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte Studies from regions where both viruses circulate have found significantly higher rates of cirrhosis and liver cancer in people with dual infection compared to HBV alone.30PubMed. Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in Upper Egypt: Prevalence and clinical features Because HDV piggybacks entirely on HBV’s envelope, hepatitis B vaccination effectively prevents hepatitis D as well.
Occult Hepatitis B
Not every HBV infection shows up on standard screening. Occult hepatitis B refers to a state in which HBsAg tests come back negative, but replication-competent HBV DNA is still present in the liver, sometimes with trace amounts detectable in the blood. The virus is not gone; it is hiding at very low levels, kept in check by the immune system but not eliminated.31PubMed Central. Occult Hepatitis B Virus Infection: An Update
This matters in several practical scenarios. Blood or organ donations from individuals with occult HBV can transmit the virus to recipients, causing classic hepatitis B. And if a person with occult infection undergoes immunosuppressive therapy, such as chemotherapy, organ transplant drugs, or certain biologic medications for autoimmune diseases, the virus can reactivate, sometimes with severe or even fatal consequences.31PubMed Central. Occult Hepatitis B Virus Infection: An Update This is why doctors routinely test for hepatitis B markers before starting potent immunosuppressive treatments, even in patients who have no known history of infection.
Effects Beyond the Liver
Although the liver is HBV’s primary target, chronic infection can affect other organ systems. Roughly one in five patients with chronic hepatitis B experiences extrahepatic manifestations, which include inflammation of blood vessels (polyarteritis nodosa), certain types of kidney disease (glomerulonephritis), joint inflammation that resembles but is not rheumatoid arthritis, and in some cases, non-Hodgkin lymphoma.32PubMed Central. Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy These conditions are driven by immune complexes, clumps of viral antigens and antibodies that deposit in tissues and trigger inflammation far from the liver. Antiviral therapy that suppresses HBV replication often improves these extrahepatic conditions, reinforcing the link between viral activity and the immune-mediated damage outside the liver.
An Ancient Human Companion
HBV is not a recent arrival. Analysis of ancient DNA extracted from human remains has revealed that the virus has circulated among humans for at least 10,000 years, and possibly much longer. A large-scale study reconstructing HBV genomes from 137 ancient Eurasian and Native American individuals dated the most recent common ancestor of all known HBV lineages to between roughly 20,000 and 12,000 years ago, placing the virus among early Holocene hunter-gatherer populations in both Europe and South America.33PubMed. Ten millennia of hepatitis B virus evolution Earlier work on Neolithic-era European genomes found HBV strains that have no close modern relatives and are most similar to viruses currently found in African non-human primates, suggesting that entire lineages of the virus have gone extinct over the millennia.34eLife. Neolithic and medieval virus genomes reveal complex evolution of hepatitis B
This long evolutionary history helps explain HBV’s remarkable adaptations to human biology, including its exploitation of a liver-specific receptor, its ability to establish a persistent nuclear template, and its capacity to modulate immune responses in ways that favor decades-long coexistence with its host. It also complicates efforts at eradication: we are dealing with a pathogen that has been fine-tuning its relationship with us for longer than recorded civilization.